Organogenesis (NASDAQ:ORGO – Get Free Report) and GRAIL (NASDAQ:GRAL – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, profitability, risk, dividends, earnings and analyst recommendations.
Analyst Ratings
This is a summary of current ratings and price targets for Organogenesis and GRAIL, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Organogenesis | 1 | 2 | 0 | 0 | 1.67 |
| GRAIL | 1 | 6 | 5 | 0 | 2.33 |
Organogenesis presently has a consensus target price of $4.33, suggesting a potential upside of 384.17%. GRAIL has a consensus target price of $128.80, suggesting a potential upside of 10.22%. Given Organogenesis’ higher possible upside, equities analysts plainly believe Organogenesis is more favorable than GRAIL.
Earnings and Valuation
This table compares Organogenesis and GRAIL”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Organogenesis | $564.17 million | 0.21 | $37.03 million | ($1.22) | -0.73 |
| GRAIL | $147.17 million | 35.70 | -$408.35 million | ($9.50) | -12.30 |
Organogenesis has higher revenue and earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Organogenesis has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500. Comparatively, GRAIL has a beta of 2.86, suggesting that its share price is 186% more volatile than the S&P 500.
Profitability
This table compares Organogenesis and GRAIL’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Organogenesis | -39.34% | -55.28% | -23.72% |
| GRAIL | -243.80% | -16.13% | -14.38% |
Institutional & Insider Ownership
49.6% of Organogenesis shares are held by institutional investors. 18.8% of Organogenesis shares are held by company insiders. Comparatively, 1.8% of GRAIL shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Organogenesis beats GRAIL on 8 of the 14 factors compared between the two stocks.
About Organogenesis
Organogenesis Holdings Inc. is a regenerative medicine company that develops, manufactures and commercializes products for advanced wound care and surgical and sports medicine. The company’s products are designed to support tissue repair and healing in a range of clinical settings. Its portfolio includes wound-care products such as Apligraf, a bioengineered skin substitute, and products made from or incorporating materials including placental tissue and purified collagen. Organogenesis also offers products for surgical and sports medicine applications.
About GRAIL
GRAIL, Inc. is a healthcare company developing blood-based tests for the early detection of multiple cancers. Its approach analyzes patterns in cell-free DNA, including DNA methylation signals, to help identify a possible cancer signal and predict its origin in the body. GRAIL’s flagship product is Galleri, a multi-cancer early detection test intended for use alongside—not as a replacement for—recommended cancer screening. The company also conducts clinical research to evaluate the test and advance its early-detection technology.
Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.
